Home > Healthcare > Medical Devices > Diagnostic Devices > Liver Disease Diagnostics Market

Liver Disease Diagnostics Market Size

  • Report ID: GMI7939
  • Published Date: Jan 2024
  • Report Format: PDF

Liver Disease Diagnostics Market Size

Liver Disease Diagnostics Market size was valued at around USD 39.5 billion in 2023 and is estimated to grow at 7.3% CAGR from 2024 to 2032. The increasing prevalence of liver diseases, growing awareness regarding liver related complications and the importance of early diagnosis, rising geriatric population, and continuous advancements in diagnostic technologies.

 

Moreover, the high prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and liver cirrhosis, is a major concern for people with sedentary lifestyles and weak immunity. Obesity, viral infections, alcohol and drug consumption, among other factors are contributing to the rising burden of liver disorders in the world. For instance, as per the article published by Clinical and Molecular Hepatology, NAFLD affects around 32% of individuals worldwide, with a greater incidence among males (40%) than females (26%).

 

Liver disease diagnostics refer to the various methods and procedures employed to identify, assess, and monitor diseases or conditions affecting the liver. The liver is a vital organ responsible for numerous functions, including detoxification, metabolism, and the production of proteins necessary for blood clotting. Liver diseases encompass a wide range of conditions, such as hepatitis, cirrhosis, fatty liver disease, and liver cancer.

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for liver disease diagnostics was valued at around USD 39.5 billion in 2023 and is estimated to reach over USD 74.6 billion by 2032 owing to the increasing prevalence of liver diseases, growing awareness regarding liver related complications and the importance of early diagnosis.

The laboratory tests segment of market accounted for over 38.1% share in 2023 and is anticipated to witness notable growth through 2032 as these tests are commonly prescribed in various clinical settings to screen for liver diseases.

North America market accounted for USD 16.2 billion in 2023 and is estimated to witness substantial market growth over 2024 and 2032 due to the obesity pandemic prevalent in the region.

Abbott Laboratories, BioMerieux SA, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd., F. Hoffmann-La Roche Ltd., HORIBA Medical, Laboratory Corporation of America Holdings, Meril Life Sciences Pvt. Ltd., Qiagen N.V., Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.

Liver Disease Diagnostics Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 214
  • Countries covered: 22
  • Pages: 110
 Download Free Sample